International Journal of Radiation Oncology*Biology*Physics
Biology ContributionBetter Efficacy of Synchrotron Spatially Microfractionated Radiation Therapy Than Uniform Radiation Therapy on Glioma
Introduction
Although many cancers are currently treated by radiation therapy, scientists and clinicians continually seek more effective, safer means to deliver radiation therapy to the tumor targets without damaging surrounding healthy tissue. Synchrotron microbeam radiation therapy (MRT), a preclinical alternative radiation therapy, is based on the spatial fractionation of the incident synchrotron beam into arrays of parallel microbeams, which are typically a few tens of microns wide, separated by a few hundreds of microns [which has been reviewed previously (1)]. This unique use of synchrotron-generated x-ray beams is characterized by kilovoltage energy, high flux, and minimal divergence. It allows the targeted deposition of a very high dose, known as the peak dose (several hectograys), in tumors by the microbeams. In contrast, the valley area, that is, the tissue area between the microbeam paths, receives a lower dose (a few grays) known as the valley dose.
Although MRT has been shown to slow or even stop the growth of several tumor types 2, 3, 4, 5, 6, 7, 8, a surprisingly high tolerance has been observed for normal tissues 4, 5, 9, 10, 11, 12, 13, 14, 15. Several mechanisms have been suggested, including cytotoxic effects on tumor cells (16) and endothelial cells; a decrease in blood vessel number 4, 17, leading to decreased perfusion (4) and tumor hypoxia (9) or, on the contrary, normalization of the vasculature (17); modulation of the immune system 18, 19, 20; and communication between lethally irradiated cells in the microbeam path and slightly damaged cells located between microbeams (21). However, the specific contribution of microbeam components has never been clearly demonstrated in vivo.
In this article, we present an assessment of the efficacy of MRT by comparing it with synchrotron broad beam (BB) radiation therapy at a dose equivalent to the dose deposited in the MRT valley area. The complex geometry of MRT, with its alternating high and low doses deposited in micrometric volumes, makes this comparison very difficult. Recent advances in theoretical and experimental dosimetry have made it possible to accurately determine the valley dose for this study. In the protocol used in this study, rats bearing intracranial 9L brain tumors were treated by 3 irradiation modalities: synchrotron x-ray irradiation in the BB mode or MRT with a valley dose corresponding to the full dose deposited by the BB or to half of that dose. The efficacy of those treatments was determined based on animal survival and tumor growth. The impact of BB irradiation and MRT at equivalent valley doses on tumor cell proliferation, the mitotic process, and inflammatory responses in the tumor bed were also studied by histology and tracking of transcriptomic modulation over a period of 15 days.
Section snippets
Methods
Procedures related to animal care conformed to the French government guidelines, under license numbers 380325 and B3818510002. Rats were anesthetized with isoflurane (5% in air) before intraperitoneal injection of a combination of xylazine (64.5 mg/kg) and ketamine (5.4 mg/kg) for tumor implantation or isoflurane, 2.5%, for magnetic resonance imaging examination and irradiation.
Monte Carlo simulations and dose calculations
The dose rate measured in reference conditions amounted to 72 Gy ⋅ s−1 ⋅ mA−1. According to Monte Carlo simulations, the relationship between the peak dose (Dpeak) and the reference dose (Dreference) can be expressed as follows: the peak dose at 7MM of depth in rat brain, that is, Dpeak Rat(7 mm) = Dreference (water at 2 cm) × 0.88. The valley dose (Dvalley) can be calculated using the PVDR, that is, Dvalley Rat(7 mm) = Dpeak Rat(7 mm)/PVDR. Thus, for a 400-Gy peak dose, the Dreference was
Discussion
The choice of the dose applied with spatially nonfractionated radiation therapy remains critical for reliable comparison with MRT. The complex irradiation geometry is very challenging for the accurate determination of the dose received by the tissue between the microbeams (valley dose; detailed in Appendix E1; available online at www.redjournal.org). Thanks to the latest advances, we can present a comparison of spatially fractionated radiation therapy (400 Gy) to BB radiation therapy deposing
Conclusion
Thanks to recent advances in dosimetry, MRT reveals clearly better efficacy in tumor control and animal lifespan than comparable uniform irradiation, showing that spatial fractionation significantly contributes to the therapeutic properties of MRT. This efficacy is not correlated with a large difference in cell proliferation or in stimulation of angiogenesis. However, the higher induction of cell death and recruitment of macrophages a few days after MRT pave the way for more extensive
References (33)
- et al.
Effects of pulsed, spatially fractionated, microscopic synchrotron X-ray beams on normal and tumoral brain tissue
Mutat Res
(2010) - et al.
Biological mechanisms underlying the X-ray microbeam effects of preferentially destroying tumors [abstract No. Dilm0599]
- et al.
Radiosurgical palliation of aggressive murine SCCVII squamous cell carcinomas using synchrotron-generated X-ray microbeams
Br J Radiol
(2006) - et al.
Preferential effect of synchrotron microbeam radiation therapy on intracerebral 9L gliosarcoma vascular networks
Int J Radiat Oncol Biol Phys
(2010) - et al.
Neuropathology of ablation of rat gliosarcomas and contiguous brain tissues using a microplanar beam of synchrotron-wiggler-generated X rays
Int J Cancer
(1998) - et al.
Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy
Neuro Oncol
(2002) - et al.
Irradiation of intracerebral 9L gliosarcoma by a single array of microplanar x-ray beams from a synchrotron: Balance between curing and sparing
Phys Med Biol
(2008) - et al.
Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors
J Synchrotron Radiat
(2012) - et al.
Synchrotron microbeam radiation therapy induces hypoxia in intracerebral gliosarcoma but not in the normal brain
Radiother Oncol
(2013) - et al.
Subacute neuropathological effects of microplanar beams of x-rays from a synchrotron wiggler
Proc Natl Acad Sci U S A
(1995)
In vivo two-photon microscopy study of short-term effects of microbeam irradiation on normal mouse brain microvasculature
Int J Radiat Oncol Biol Phys
Brain tumor vessel response to synchrotron microbeam radiation therapy: A short-term in vivo study
Phys Med Biol
Response of avian embryonic brain to spatially segmented x-ray microbeams
Cell Mol Biol
Response of rat skin to high-dose unidirectional x-ray microbeams: A histological study
Radiat Res
Identification of AREG and PLK1 pathway modulation as a potential key of the response of intracranial 9L tumor to microbeam radiation therapy
Int J Cancer
Cited by (60)
Novel unconventional radiotherapy techniques: Current status and future perspectives – Report from the 2nd international radiation oncology online seminar
2023, Clinical and Translational Radiation OncologyCombining FLASH and spatially fractionated radiation therapy: The best of both worlds
2022, Radiotherapy and OncologyMicrobeam Irradiation of the Beating Rodent Heart: An Ex Vivo Study of Acute and Subacute Effects on Cardiac Function
2022, International Journal of Radiation Oncology Biology PhysicsA Brief Overview of the Preclinical and Clinical Radiobiology of Microbeam Radiotherapy
2021, Clinical OncologyA Mouse Model for Microbeam Radiation Therapy of the Lung
2021, International Journal of Radiation Oncology Biology Physics
Laurent Pelletier and Géraldine Le Duc contributed equally.
This project was partially funded by the French National Cancer Institute (Institut National du Cancer, Bioresys Project No. 200187) and by La Ligue Nationale Contre le Cancer–Comité de Haute Savoie. The Grenoble magnetic resonance imaging facility IRMaGe was partly funded by the French program Investissement d'Avenir run by the Agence Nationale pour la Recherche (Infrastructure d'Avenir en Biologie Santé grant No. ANR-11-INBS-0006).
Conflict of interest: none.